MX2009011949A - Inhibidores de proteina activadora de 5-lipoxigenasa (flap). - Google Patents

Inhibidores de proteina activadora de 5-lipoxigenasa (flap).

Info

Publication number
MX2009011949A
MX2009011949A MX2009011949A MX2009011949A MX2009011949A MX 2009011949 A MX2009011949 A MX 2009011949A MX 2009011949 A MX2009011949 A MX 2009011949A MX 2009011949 A MX2009011949 A MX 2009011949A MX 2009011949 A MX2009011949 A MX 2009011949A
Authority
MX
Mexico
Prior art keywords
flap
lipoxygenase
activating protein
inhibitors
compounds
Prior art date
Application number
MX2009011949A
Other languages
English (en)
Inventor
Petpiboon Peppi Prasit
Mark Moran
Jillian F Evans
Yiwei Li
Bowei Wang
Jeannie M Arruda
Nicholas Simon Stock
Brian Andrew Stearns
Jeffrey Roger Roppe
Jasmine Eleanor Zunic
Mustapha Haddach
Jill Melissa Scott
John Howard Hutchinson
Thomas Jon Seiders
Yen Pham Truong
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of MX2009011949A publication Critical patent/MX2009011949A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos y composiciones farmacéuticas que contienen tales compuestos, los cuales modulan la actividad de la proteína activadora de 5-lipoxigenasa (FLAP). En la presente también se describen métodos para utilizar estos moduladores de FLAP, solos y en combinación con otros compuestos, para el tratamiento de condiciones o enfermedades respiratorias, cardiovasculares, y otras condiciones o enfermedades dependientes de leucotrienos o mediadas por leucotrienos.
MX2009011949A 2007-05-04 2008-05-01 Inhibidores de proteina activadora de 5-lipoxigenasa (flap). MX2009011949A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/744,555 US20070219206A1 (en) 2005-11-04 2007-05-04 5-lipoxygenase-activating protein (flap) inhibitors
PCT/US2008/062310 WO2008137609A1 (en) 2007-05-04 2008-05-01 5-lipoxygenase-activating protein (flap) inhibitors

Publications (1)

Publication Number Publication Date
MX2009011949A true MX2009011949A (es) 2010-01-26

Family

ID=39944363

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011949A MX2009011949A (es) 2007-05-04 2008-05-01 Inhibidores de proteina activadora de 5-lipoxigenasa (flap).

Country Status (17)

Country Link
US (1) US20070219206A1 (es)
EP (1) EP2144875A4 (es)
JP (1) JP2010526095A (es)
KR (1) KR20100036239A (es)
CN (1) CN101687791A (es)
AR (1) AR066424A1 (es)
AU (1) AU2008247672B2 (es)
BR (1) BRPI0810696A2 (es)
CA (1) CA2686232A1 (es)
CL (1) CL2008001273A1 (es)
EA (1) EA017150B9 (es)
MX (1) MX2009011949A (es)
PE (1) PE20091891A1 (es)
SG (1) SG185872A1 (es)
TW (1) TW200843737A (es)
UY (1) UY31067A1 (es)
WO (1) WO2008137609A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20100068301A1 (en) 2006-11-30 2010-03-18 Hutchinson John H Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
US20100298343A1 (en) * 2007-10-05 2010-11-25 John Howard Hutchinson 5-lipoxygenase-activating protein (flap) inhibitors
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
KR20160129109A (ko) * 2008-05-23 2016-11-08 아미라 파마슈티칼스 인코포레이티드 5-리폭시게나아제 활성화 단백질 억제제
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP2012513406A (ja) * 2008-12-23 2012-06-14 パンミラ ファーマシューティカルズ，エルエルシー． 皮膚科学の疾病の処置のためのｆｌａｐ阻害剤の局所製剤
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
TW201107315A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
PE20130751A1 (es) * 2010-08-16 2013-06-21 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrieno
EP3360552A1 (en) 2010-12-07 2018-08-15 Amira Pharmaceuticals, Inc. Polycyclic lpa1 antagonist and uses thereof
BR112013014019A2 (pt) 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
EP2694496A1 (en) 2011-04-05 2014-02-12 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
WO2012166415A1 (en) 2011-05-27 2012-12-06 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP3906925A1 (en) 2014-02-04 2021-11-10 Bioscience Pharma Partners, LLC Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
EP2949653A1 (en) 2014-05-27 2015-12-02 Banoglu, Erden Isoxazole derivatives as leukotriene biosynthesis inhibitors
MX2017011269A (es) 2015-03-06 2018-01-12 Pharmakea Inc Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos.
KR102587178B1 (ko) 2016-09-07 2023-10-06 파마케아, 인크. 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법
EP4385571A2 (en) 2016-09-07 2024-06-19 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor related applications
CA3066361A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
CN111556763B (zh) 2017-11-13 2023-09-01 施菲姆德控股有限责任公司 血管内流体运动装置、系统
EP3746149A4 (en) 2018-02-01 2021-10-27 Shifamed Holdings, LLC INTRAVASCULAR BLOOD PUMPS AND METHODS OF USE AND METHODS OF MANUFACTURING
CN109535060B (zh) * 2018-12-20 2022-03-25 苏州麦迪耐斯医药科技有限公司 一种刺猬通路抑制剂及其制备方法和应用
WO2021011473A1 (en) 2019-07-12 2021-01-21 Shifamed Holdings, Llc Intravascular blood pumps and methods of manufacture and use
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US11724089B2 (en) 2019-09-25 2023-08-15 Shifamed Holdings, Llc Intravascular blood pump systems and methods of use and control thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60123485A (ja) * 1983-12-08 1985-07-02 Yoshitomi Pharmaceut Ind Ltd インド−ル−３−カルボキサミド誘導体
IL84796A (en) * 1986-12-17 1992-03-29 Merck Frosst Canada Inc Substituted n-benzyl-indoles and pharmaceutical compositions containing them
US5225421A (en) * 1986-12-17 1993-07-06 Merck Frosst Canada, Inc. 3-hetero-substituted-N-benzyl-indoles and medical methods of use therefor
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
US5232916A (en) * 1988-06-27 1993-08-03 Merck Frosst Canada, Inc. Quinoline ether alkanoic acids
US5272145A (en) * 1989-08-22 1993-12-21 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5204344A (en) * 1989-08-22 1993-04-20 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indoles as inhibitors of the biosynthesis of leukotrienes
US5252585A (en) * 1992-02-03 1993-10-12 Merck Frosst Canada, Inc. Fluorinated quinoline indoles as inhibitors of the biosynthesis of leukotrienes
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5229516A (en) * 1989-10-27 1993-07-20 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
JPH0764841B2 (ja) * 1990-10-03 1995-07-12 ファイザー製薬株式会社 インドール誘導体およびその用途
US5190968A (en) * 1991-09-30 1993-03-02 Merck Frosst Canada, Inc. (Polycyclic-arylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5273980A (en) * 1991-09-30 1993-12-28 Merck Frosst Canada Inc. Bicyclic-azaarylmethoxy) indoles as inhibitors of leukotriene biosynthesis
US5308850A (en) * 1991-09-30 1994-05-03 Merck Frosst Canada, Inc. (Bicyclic-hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5290798A (en) * 1991-09-30 1994-03-01 Merck Frosst Canada, Inc. (hetero-arylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5389650A (en) * 1991-09-30 1995-02-14 Merck Frosst Canada, Inc. (Azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5254567A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds which have useful pharmaceutical utility
AU3488693A (en) * 1992-02-13 1993-09-03 Merck Frosst Canada Inc. (Azaaromaticalkoxy)indoles as inhibitors of leukotriene biosynthesis
US5334719A (en) * 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5288743A (en) * 1992-11-20 1994-02-22 Abbott Laboratories Indole carboxylate derivatives which inhibit leukotriene biosynthesis
US5374635A (en) * 1993-03-29 1994-12-20 Merck Frosst Canada, Inc. Furo[3,2-b]pyridines and thieno[3,2-b]pyridines as inhibitors of leukotriene biosynthesis
US5399699A (en) * 1994-01-24 1995-03-21 Abbott Laboratories Indole iminooxy derivatives which inhibit leukotriene biosynthesis
FR2721610B1 (fr) * 1994-06-28 1996-08-23 Adir Nouveaux dérivés (thia)cycloalkyl [b] indoles, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5750558A (en) * 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US6867209B1 (en) * 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
DE602005015962D1 (de) * 2004-05-03 2009-09-24 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
ES2379987T3 (es) * 2005-10-11 2012-05-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compuestos de benzofurano marcados isotópicamente como radiotrazadores para proteínas amiloidógenas
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US20070244128A1 (en) * 2005-11-04 2007-10-18 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) * 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Also Published As

Publication number Publication date
EA200901308A1 (ru) 2010-04-30
JP2010526095A (ja) 2010-07-29
US20070219206A1 (en) 2007-09-20
PE20091891A1 (es) 2010-01-07
CN101687791A (zh) 2010-03-31
EA017150B1 (ru) 2012-10-30
UY31067A1 (es) 2009-01-05
AR066424A1 (es) 2009-08-19
WO2008137609A1 (en) 2008-11-13
TW200843737A (en) 2008-11-16
EP2144875A4 (en) 2011-02-09
EP2144875A1 (en) 2010-01-20
BRPI0810696A2 (pt) 2014-10-21
AU2008247672B2 (en) 2013-04-11
CL2008001273A1 (es) 2008-09-22
SG185872A1 (en) 2012-12-28
EA017150B9 (ru) 2013-03-29
KR20100036239A (ko) 2010-04-07
CA2686232A1 (en) 2008-11-13
AU2008247672A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2009011949A (es) Inhibidores de proteina activadora de 5-lipoxigenasa (flap).
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2009045700A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2010021693A3 (en) Mif modulators
WO2010025295A3 (en) Compounds that modulate intracellular calcium
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2010002712A (es) Compuestos que modulan calcio intracelular.
WO2011140202A3 (en) Mif modulators
WO2009076454A3 (en) Compounds that modulate intracellular calcium
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2011139489A3 (en) Compounds that modulate intracellular calcium
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
WO2012027710A3 (en) Compounds that modulate intracellular calcium
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
WO2011139765A3 (en) Compounds that modulate intracellular calcium
WO2011034962A3 (en) Compounds that modulate intracellular calcium
WO2011109551A3 (en) Compounds that modulate intracellular calcium
WO2012040511A3 (en) Compounds that modulate intracellular calcium
WO2006072951A3 (en) Compositions and methods for regulating apoptosis
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности

Legal Events

Date Code Title Description
HH Correction or change in general
GB Transfer or rights

Owner name: PANMIRA PHARMACEUTICALS, LLC.*

FA Abandonment or withdrawal